← All sarcoma trials
Recruiting nowN/AAges 18 Years and up

Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy

Sponsor: Centre Antoine Lacassagne · NCT06029218 on ClinicalTrials.gov ↗

Conditions studied

ChordomaChondrosarcomaEwing SarcomaOsteosarcoma

What it tests

  • Proteus ONE one daily beamradiation
  • Proteus ONE two daily beamradiation

Where it's running1 site

1 international site
  • Centre Antoine lacassagne

    Nice, France 06000

    Recruiting now
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Chordoma, chondrosarcoma of the skull base and spine, Ewing's sarcoma, and osteosarcoma meeting the criteria for treatment by proton therapy
* Tumour requiring 2 beams
* MRI less than one month old
* PS 0-2.
* Patient who has read the patient information note and signed the consent form.
* Patient with healthcare insurance cover.
* Age over 18 years.
* For women of childbearing age, negative urine pregnancy test and effective contraception in place for the duration of treatment and for six months following the end of treatment.

Exclusion Criteria:

* Persons deprived of their liberty or under guardianship.
* Unable to undergo the medical follow-up of the clinical investigation for geographical, social or psychological reasons.
* Patient eligible for symptom reduction surgery Vulnerable populations and participants defined in Articles 64 to 68 of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017.

Updated 2024-09-25 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.